CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer
Seung Tae Kim, Tae Won Kim, Kyu-pyo Kim, Tae-You Kim, Sae-Won Han, Ji Yun Lee, Sung Hee Lim, Min-Young Lee, Haesu Kim, Young Suk Park
Cancer Research and Treatment. 2015;47(4):790-795.   Published online 2014 December 2    DOI: https://doi.org/10.4143/crt.2014.126

Excel Download

Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer
Cancer Research and Treatment. 2014;47(4):790-795   Crossref logo
Link1 Link2 Link3

Towards shedding some light on regorafenib treatment in refractory metastatic colorectal cancer
ESMO Open. 2017;2(3):e000205   Crossref logo
Link1 Link2 Link3

P-159 Regorafenib vs TAS-102 as salvage-line treatment in patients with metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study
Annals of Oncology. 2016;27:ii47   Crossref logo
Link1 Link2 Link3

Regorafenib or Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer? A Perspective on the Basis of Pharmacological Costs
Clinical Colorectal Cancer. 2018;17(2):e381-e383   Crossref logo
Link1 Link2

Palliative treatment of refractory metastatic colorectal cancer using regorafenib: Macau experience
Annals of Oncology. 2017;28:x45   Crossref logo
Link1 Link2 Link3

Trifluridine/tipiracil vs regorafenib as salvage-line treatment in patients with metastatic colorectal cancer: A multicenter retrospective study
Annals of Oncology. 2018;29:v65   Crossref logo
Link1 Link2 Link3

Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States
Clinical Colorectal Cancer. 2018;17(4):e751-e761   Crossref logo
Link1 Link2

Regorafenib: Novel treatment for refractory colorectal cancer
Pharmacy Today. 2012;18(11):40   Crossref logo
Link1 Link2

Treatment of Refractory Colorectal Cancer: Regorafenib vs. TAS-102
Current Colorectal Cancer Reports. 2017;13(4):325-333   Crossref logo
Link1 Link2 Link3

Optimizing Treatment Sequence for Late-line Metastatic Colorectal Cancer Patients Using Trifluridine/Tipiracil and Regorafenib
Clinical Colorectal Cancer. 2018;17(4):274-279   Crossref logo
Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.